ABCC8 p.Val1523Met

[switch to full view]
Comments [show]
Publications
PMID: 21953423 [PubMed] Iafusco D et al: "Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births."
No. Sentence Comment
36 In patients with NDM, we identified a causative mutation in 11 cases with permanent diabetes (7 KCNJ11 and 4 INS) (3,4; and the frequent KCNJ11/R201H mutation in a patient born in September 2010) and 7 with transient diabetes (mutations: ABCC8/ S459R, ABCC8/R1380C, ABCC8/V1523M, KCNJ11/ R50Q (twice), KCNJ11/E229K, and 1 case with UDP6).
X
ABCC8 p.Val1523Met 21953423:36:272
status: NEW
Login to comment

37 Transient neonatal diabetes mutations KCNJ11/R50H, KCNJ11/E229K, and ABCC8/R1380C have been previously reported [14], while ABCC8 mutations in same residue as ours, but with different amino acid change such as V1523A/L have been described associated with permanent neonatal diabetes [14].
X
ABCC8 p.Val1523Met 21953423:37:272
status: NEW
Login to comment

PMID: 17389331 [PubMed] Vaxillaire M et al: "New ABCC8 mutations in relapsing neonatal diabetes and clinical features."
No. Sentence Comment
38 We identified eight heterozygous missense ABCC8 mutations in 8 of the 16 patients with neonatal diabetes, six of which have not yet been reported: E208K (c.622GϾA), A269D (c.806CϾA), V324M (c.970GϾA), R825W (c.2473CϾT), R1379H (c.4136GϾA), and V1523M (c.4567GϾA) (Fig. 1).
X
ABCC8 p.Val1523Met 17389331:38:274
status: NEW
Login to comment

39 The two other mutations, L582V (c.1744CϾG) and R1182Q (c.3545GϾA), had been previously described by our group in three independent families with TND cases (13).
X
ABCC8 p.Val1523Met 17389331:39:274
status: NEW
Login to comment

44 V324M is located in the transmembrane domain (TMD)6 of TMD1, and R1379H and V1523M are in the nucleotide-binding domain 2, the domain argued to hydrolyze MgATP.
X
ABCC8 p.Val1523Met 17389331:44:76
status: NEW
Login to comment

45 A269D and R825W lie in the helical intracellular coupling domains (4).
X
ABCC8 p.Val1523Met 17389331:45:76
status: NEW
Login to comment

51 The R1182Q and V1523M mutations were not identified in either parent, consistent with de novo mutations.
X
ABCC8 p.Val1523Met 17389331:51:15
status: NEW
Login to comment

52 The V324M and R1379H mutations tested negative in the mothers, and the two fathers were not available for genetic testing.
X
ABCC8 p.Val1523Met 17389331:52:15
status: NEW
Login to comment

77 In the ND-SUR1 patients, an apparently mild phenotype, i.e., without neurological features, is observed in the TND families, except in a few cases presenting with PND (13) TABLE1 ClinicalfeaturesinneonataldiabeticpatientsscreenedpositiveforABCC8mutations Patient SGMGKKSLMCNCDDLNJ MutationE208KV324ML582VR825WR1182QR1379HV1523MA269D SexFemaleMaleMaleFemaleFemaleMaleMaleFemale TypeofdiabetesTNDTNDTNDTNDTNDTNDPND Notyet known Atbirth Weight(g/percentile)1,790/321,660/Ͻ33,250/282,300/Ͻ32,930/103,150/432,710/312,390/Ͻ3 Gestationweek33.53739394138.53739 Atpresentation Age(days)1112361013426766 Weight(g)1,7904,2904,3002,5203,0003,6903,6605,100 PresentationGlucose monitoring KetoacidosisKetoacidosisGlucose monitoring WeightlossKetoacidosisKetoacidosisKetoaciduria Glucose(mmol/l)12.424.160.516.824.164.23627.5 Autoantibodies00000000 Insulindose(units⅐kg-1 ⅐day-1 )0.1012.400.300.720.502.500.72 PancreasultrasonographyNANANNNNNN Currentstatus Age(months)712728134833188.7 Height(cm/SD)63/-1.6134.5/-0.790.2/0.672.5/-0.4101.2/0.296/184/1.370/0.8 Weight(kg/percentile)6.15/323.6/Ͻ313.5/759.62/5614.9/5017.5/Ͼ9711/318.52/50 Diabetes(yes[ϩ],no[-])-ϩ(9)*----ϩϩ Insulindose(units⅐kg-1 ⅐day-1 )00†00000.600.62 A1Catlastexamination(%)4.56.05.15.05.45.05.58.9 Neurologicalfeatures MuscleweaknessNoNoNoNoNoNoNoNo MotordevelopmentaldelayNoNoNoNoNoNoNoNo EpilepsyNoNoNoNoNoNoNoNo MentaldevelopmentaldelayNoNoNoNoNoNoNoNo SpeechdevelopmentaldelayNoYesNoNoNoYesNoNo DysmorphicfeaturesNoNoNoNoNoNoNoNo OtherfeaturesNoNoNoNoNoHyperkinesia, troubleof feeding behavior NoHypotonia ParentwithamutationFatherNone‡FatherFatherNoneNone‡NoneMother Glucosetolerance§IGT-NN---N Ageatexamination(year)41-3129---25 A1Catlastexamination(%)¶5.4-6.1NA---5.2 BMIatlastexamination(kg/m2 )27-2422---NA *Ageatrelapse,inyear.†PatientGK-V324Mwassuccessfullyswitchedtoglibenclamide(gliburide)attheageof9.5years(currentdose2.5mg/day;weight25kg).‡Onlythemotherwas screenedforthemutation;thefatherofGK-V324Mdied,andnoinformationisavailableonthebiologicalfatherofCD-R1379H.§Assessedbyanoralglucosetolerancetest.¶Upperlimit ofnormalvaluesforA1C:5.6%.IGT,impairedglucosetolerance;N,normal;NA,notavailable.
X
ABCC8 p.Val1523Met 17389331:77:347
status: NEW
Login to comment